VCYTVeracyte, Inc.

$45.23+33% 1Y

$45.23

$30.0152 weeks$59.55

VCYT in its own filings

Nothing in VCYT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

251

Events found in the filings · across 1,170 filings · the record starts in 2013

Hard flags: none
Hard flags
Most recent filing: Sep 14, 2026
Most recent filing · Form 8-K
Record starts: Sep 10, 2013
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 3, 2026
Change in certifying accountanthistorical: 2014-06-10
SEC comment-letter activity31 occurrences: 2024-06-13

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 14, 2026Merger Agreement On September 10, 2026, Veracyte, Inc., a Delaware corporation (“Veracyte”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Compass Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Veracyte (“Merger Sub”), Convergent Genomics Inc., a Delaware …Material agreement entered · Form 8-K
Mar 16, 2026On March 16, 2026, Veracyte, Inc. (the “Company”) announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

opening the record…